Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Contract Development Services, Advanced Medicine, Contract Manufacturing Services

Twenty-First Century Cell Therapy

In August, The Medicine Maker’s advanced medicines supplement illustrated the explosive growth of the cell therapy industry (1). Over the last decade, the industry has moved from great expectations to clinical realities, with a growing number of ongoing clinical trials in multiple indications. Clinical trials are now primarily sponsored and driven by industry, rather than academia – an exciting feature of the maturing field. There is also growing acceptance that allogeneic products will not completely replace autologous transplantation approaches – there will be a need for both systems. As more autologous therapies come to market, the industry is also getting to grips with the supply chain and business model challenges.

Initially, approved cell therapy products tended to be focused on regenerative medicine and tissue engineering, but now the field has shifted to immunotherapy. Novartis’ CAR-T therapy, Kymriah, will hit the market soon, after being approved by the FDA at the end of August. It will be manufactured for each individual patient using their own cells and cryopreserved to allow for treatment flexibility. Other companies are also hoping for CAR-T approvals; for example, Kite Pharma won the 2017 “Clinical Trial Result of the Year” for its Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma at the Clinical and Research Excellence Awards. It’s safe to say that immunotherapy and cell therapies are in the spotlight.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Denis Bedoret

Denis Bedoret is Managing Director at Masthercell, Belgium

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register